Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform. CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear® properties. In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.
Company Details
- Founded
- -
- Address
- 1 Deerpark Dr, E,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- elucidaoncology.com
- HQ
- Monmouth Junction, NJ
Elucida Oncology, Inc. Questions
Elucida Oncology, Inc.'s website is elucidaoncology.com
Elucida Oncology, Inc.'s LinkedIn profile is https://www.linkedin.com/company/elucida-oncology-inc.
Elucida Oncology, Inc.'s industry is
Biotechnology Research
Elucida Oncology, Inc.'s top competitors are
Sapience Therapeutics, Inc.,
Novarock Biotherapeutics Ltd,
Contrafect Corp,
Biocept, Inc.,
Iterum Therapeutics Plc,
Elicio Therapeutics,
Gensight Biologics,
Sage Therapeutics,
Tessera Therapeutics,
Dash Bio.
Elucida Oncology, Inc.'s categories are Biotechnology Research
Elucida Oncology, Inc.'s founding year is 2014
